On May 5, 2025, Eli Lilly held its annual shareholder meeting where 846.6 million shares voted, approving four director nominees and the auditor but rejecting amendments to eliminate the classified board structure and supermajority voting. The advisory compensation for executives was also approved, receiving 731.4 million votes in favor.